Tags

Type your tag names separated by a space and hit enter

A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure.
Am J Cardiol 1987; 60(5):72C-74CAJ

Abstract

Enoximone (MDL 17,043), a newly synthesized imidazole derivate, has been shown to possess both positive inotropic and vasodilating properties. Sixteen patients with congestive heart failure were allocated to receive either enoximone, 50, 100 or 150 mg, or placebo, each given 3 times daily for 4 weeks, to investigate the dose-related efficacy and tolerability of oral enoximone. Symptom-limited exercise capacity improved in 5 of 10 patients in the enoximone group. The ejection fraction increased from 28% to 36% after 4 weeks, to 36% after 8 weeks and to 35% after 12 weeks in the enoximone group. Exercise duration and ejection fraction did not change in the patients in the placebo group. With enoximone, heart rate, blood pressure, Holter monitoring and laboratory tests showed no significant drug-related changes. The addition of oral enoximone to existing therapy with digitalis and diuretics may improve the clinical condition and left ventricular function in patients with congestive heart failure. Enoximone shows clinical efficacy at dosages of 50 mg and 100 mg 3 times daily. With the higher dosage, unwanted side effects increased but efficacy did not. Enoximone did not increase ventricular ectopy in the doses given.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

2956873

Citation

Zipperle, G, et al. "A Double-blind Dose Response Comparison of Oral Enoximone and Placebo for Congestive Heart Failure." The American Journal of Cardiology, vol. 60, no. 5, 1987, pp. 72C-74C.
Zipperle G, Butzer F, Dieterich HA, et al. A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure. Am J Cardiol. 1987;60(5):72C-74C.
Zipperle, G., Butzer, F., Dieterich, H. A., & Heinrich, F. (1987). A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure. The American Journal of Cardiology, 60(5), pp. 72C-74C.
Zipperle G, et al. A Double-blind Dose Response Comparison of Oral Enoximone and Placebo for Congestive Heart Failure. Am J Cardiol. 1987 Aug 14;60(5):72C-74C. PubMed PMID: 2956873.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure. AU - Zipperle,G, AU - Butzer,F, AU - Dieterich,H A, AU - Heinrich,F, PY - 1987/8/14/pubmed PY - 1987/8/14/medline PY - 1987/8/14/entrez SP - 72C EP - 74C JF - The American journal of cardiology JO - Am. J. Cardiol. VL - 60 IS - 5 N2 - Enoximone (MDL 17,043), a newly synthesized imidazole derivate, has been shown to possess both positive inotropic and vasodilating properties. Sixteen patients with congestive heart failure were allocated to receive either enoximone, 50, 100 or 150 mg, or placebo, each given 3 times daily for 4 weeks, to investigate the dose-related efficacy and tolerability of oral enoximone. Symptom-limited exercise capacity improved in 5 of 10 patients in the enoximone group. The ejection fraction increased from 28% to 36% after 4 weeks, to 36% after 8 weeks and to 35% after 12 weeks in the enoximone group. Exercise duration and ejection fraction did not change in the patients in the placebo group. With enoximone, heart rate, blood pressure, Holter monitoring and laboratory tests showed no significant drug-related changes. The addition of oral enoximone to existing therapy with digitalis and diuretics may improve the clinical condition and left ventricular function in patients with congestive heart failure. Enoximone shows clinical efficacy at dosages of 50 mg and 100 mg 3 times daily. With the higher dosage, unwanted side effects increased but efficacy did not. Enoximone did not increase ventricular ectopy in the doses given. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/2956873/A_double_blind_dose_response_comparison_of_oral_enoximone_and_placebo_for_congestive_heart_failure_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0002-9149(87)90530-3 DB - PRIME DP - Unbound Medicine ER -